Kidney cancer

Results: 780



#Item
31OTTaxitinib-for-preoperative-downstaging-of-sarcomatoid-renal-c

OTTaxitinib-for-preoperative-downstaging-of-sarcomatoid-renal-c

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2014-05-13 14:59:54
32Immunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology

Immunotherapy for Kidney Cancer: Finally Center-Stage? Nizar M. Tannir, MD, FACP Professor and Deputy Chair GU Medical Oncology

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2015-05-04 13:05:40
331st line treatment: what has changed in the last 2 years? 10th European International Kidney Cancer Symposium Lyon April 2015

1st line treatment: what has changed in the last 2 years? 10th European International Kidney Cancer Symposium Lyon April 2015

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2015-05-04 13:05:49
34My ideal bevacizumab patient? Bernard Escudier Institut Gustave Roussy, Villejuif, France Ninth European International Kidney Cancer Symposium Dublin – 25-26 April 2014

My ideal bevacizumab patient? Bernard Escudier Institut Gustave Roussy, Villejuif, France Ninth European International Kidney Cancer Symposium Dublin – 25-26 April 2014

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2014-05-13 15:04:17
35Nephron Sparing Surgery Past, Present and Future Hein Van Poppel Professor and Chairman UZ Leuven Adjunct Secretary General EAU

Nephron Sparing Surgery Past, Present and Future Hein Van Poppel Professor and Chairman UZ Leuven Adjunct Secretary General EAU

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2015-05-04 13:05:45
36Who is the ideal mTOR patient ? Thomas E Hutson, DO, PharmD, FACP Professor of Medicine Director, GU Oncology Program Co-Director, GU Center of Excellence

Who is the ideal mTOR patient ? Thomas E Hutson, DO, PharmD, FACP Professor of Medicine Director, GU Oncology Program Co-Director, GU Center of Excellence

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2014-05-13 13:28:54
37467 VERIFICATION OF A FUNCTIONALIZED STRUCTURED MEDICAL WIRE FOR THE ISOLATION OF CIRCULATING TUMOR CELLS (CTC) IN PATIENTS WITH RENAL CELL CARCINOMA

467 VERIFICATION OF A FUNCTIONALIZED STRUCTURED MEDICAL WIRE FOR THE ISOLATION OF CIRCULATING TUMOR CELLS (CTC) IN PATIENTS WITH RENAL CELL CARCINOMA

Add to Reading List

Source URL: www.gilupi.de

Language: English - Date: 2014-02-06 03:45:50
38Is Renal Cryoablation Becoming an Effective Alternative to Partial Nephrectomy? Julien Garnon & Jean Jacques Patard 51 years old man No medical past history BMI=35 Creatinin 0.8 mg/dl MDRD GFR: 102 ml/min

Is Renal Cryoablation Becoming an Effective Alternative to Partial Nephrectomy? Julien Garnon & Jean Jacques Patard 51 years old man No medical past history BMI=35 Creatinin 0.8 mg/dl MDRD GFR: 102 ml/min

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2015-05-04 13:05:40
39Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy

Sergio Bracarda MD Head, Medical Oncology Department of Oncology AUSL-8 Istituto Toscano Tumori (ITT) San Donato Hospital Arezzo, Italy

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2014-05-13 14:06:16
40Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I

Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I

Add to Reading List

Source URL: www.euikcs.com

Language: English - Date: 2015-05-04 13:05:42